Key Points Pfizer's deal with the U.S. government, a robust pipeline, and a reasonable valuation make it a compelling buy. Eli Lilly's fantastic financial results and impressive innovative abilities paint a bright picture for the future. 10 stocks we like better than Pfizer › There are several compelling reasons to invest in pharmaceutical companies, especially when the economy isn't doing well. Since they belong to a defensive industry, drugmakers tend to perform better than most companies even in ...

来源：智通财经 智通财经记者 | 黄华 智通财经编辑 | 谢欣 近日，创新药公司爱科百发再次向港交所递交了上市申请。近些年内，该公司多番冲击IPO，这已是其 五年内二度尝试港股上市。 据行业媒体药研网报道，爱科百发首次公开冲刺IPO的时间可追溯至2021年6月，当时目标是港股主 板，随后在2022年年初选择主动终止上市申请。 智通财经此前报道，2023年上半年，爱科百发放弃港交所IPO之后，正式向科创板递交了IPO招股书； 但在2024年初，爱科百发撤回了发行上市申请。 9月18日上午，就港股IPO动态一事，智通财经记者向爱科百发官网投资者关系邮箱发送了采访提纲， 截至发稿时尚未收到回复。同日上午，智通财经记者拨打了爱科百发官网联系电话，通话没有被接通。 若是从财务面看，爱科百发由于缺乏商业化产品，加之前几年的大研发投入，目前的现金状况较为糟 心，入不敷出态势严峻，这也可能促使企业再度启动IPO计划。 企业招股书显示，截至今年上半年末，爱科百发现金及现金等价物不足1亿元。但在同期，公司的研发 成本和行政开支分别是8613.8万元、1943.4万元。今年上半年，该公司继续亏损，期内亏损也过亿。 | | 截至12 ...

Key Takeaways Moderna targets $30B market with 10 new products in four years to reduce COVID-19 sales reliance.Declining Spikevax sales drive focus on RSV and late-stage pipeline programs like CMV and influenza.Cancer therapy intismeran, with Merck, advances in phase III studies for melanoma and lung cancer.Moderna (MRNA) is focusing on launching up to 10 new marketed products over the next four years, targeting a market opportunity of over $30 billion. These launches are central to Moderna’s strategy to dr ...

The company continues to improve its pipeline.The GLP-1 market has grabbed considerable attention in the past couple of years, and there's little doubt as to which pharmaceutical companies dominate this space. Eli Lilly is currently the leader, followed closely by Novo Nordisk.However, other giants in the industry have been attempting to enter the field, and Pfizer (PFE 0.64%) is among them. Although the company has encountered some setbacks in this quest, it hasn't given up, as evidenced by a recent $5 bil ...

Enanta Pharmaceuticals Inc. (ENTA) will hold a conference call and webcast on Monday, September 29, 2025, at 8:30 a.m. ET to share topline results from its RSVHR study.RSVHR is a phase 2b trial evaluating its lead drug candidate Zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults.Respiratory syncytial virus (RSV) causes severe lung infections, including bronchiolitis and pneumonia. High-risk populations include premature babies, young infants, and children. In the U.S. al ...

Core Viewpoint - Dividend stocks provide high yields and growth catalysts that can support payouts for decades, making them attractive for passive income investors [1][2]. Group 1: Dividend Stocks Overview - Building passive income through dividend-paying stocks allows investors to secure financial freedom by generating regular cash distributions [2]. - Dividend stocks combine income with potential long-term capital appreciation, offering protection against inflation through rising distributions [3]. Group 2: Company-Specific Insights - Philip Morris International offers a 3.6% yield with an 80% payout ratio, supported by its transformation towards smoke-free products, which generated 39% of 2024 revenue [6][7]. - Pfizer provides a 7.14% yield at 7.7 times forward earnings, with projected revenue of $61 billion to $64 billion in 2025, driven by various growth products and an acquisition of Metsera for up to $7.3 billion [8][9]. Group 3: Investment Considerations - Philip Morris trades at a discount with a forward earnings ratio of 19.4 compared to 22 for the S&P 500, while maintaining a credible path to smoke-free growth [7]. - Pfizer's high payout ratio of 90% presents execution risks, but management's commitment to dividends and lower expense guidance suggest a compelling risk-reward balance [9][11]. Group 4: Passive Income Strategy - Both Philip Morris and Pfizer offer different paths to passive income, with a combined yield of approximately 5.4%, significantly higher than the S&P 500 average [10]. - Sustainable yields backed by strong business fundamentals are crucial for passive income investing, with both companies demonstrating potential despite facing regulatory challenges [11].

Industry Overview - Healthcare stocks are currently at their lowest valuations in three decades, presenting potential investment opportunities for opportunistic investors [1] - The industry has faced significant challenges recently, but many healthcare stocks are available at reasonable valuations relative to their growth potential [1] Company Analysis: Pfizer - Pfizer is facing several patent cliffs, including the anticoagulant Eliquis, which will lose patent exclusivity by 2029, contributing to its poor market performance [4] - Despite recent challenges, Pfizer's revenue increased by 10% year over year to $14.7 billion in Q2, with adjusted earnings per share growing 30% to $0.78 [5] - The company has a promising pipeline, with new products like Abrysvo, a vaccine for respiratory syncytial virus, seeing a 155% revenue increase year over year to $143 million [6] - Pfizer has improved its pipeline through licensing deals and acquisitions, particularly in oncology, which is expected to yield excellent clinical results in the coming years [7] - Cost-cutting efforts are underway, with projected net savings of $4.5 billion by the end of the year and $7.2 billion by 2027, which will enhance profitability [8] Investment Consideration - The current market conditions make it a favorable time to invest in healthcare stocks, particularly Pfizer and Vertex Pharmaceuticals, as Pfizer's financial results and pipeline improvements position it well to navigate upcoming challenges [9]

Key Takeaways GSK vaccine sales fell in the U.S. as Shingrix and Arexvy declined sharply in early 2025.Revised ACIP guidance narrowed Arexvy's eligible population, hurting sales momentum.Penmenvy approval and pipeline efforts may aid growth, but benefits will take time.GSK plc (GSK) is one of the key vaccine makers in the world, marketing vaccines to help prevent infectious diseases like Respiratory Syncytial Virus or RSV, meningitis, shingles, hepatitis and many more.GSK’s Vaccine sales are declining in th ...

Core Insights - Pfizer Inc. is experiencing challenges in share price momentum post-COVID-19, but recent strong quarterly results and a favorable technical chart indicate a potential turnaround, making it a consideration for investment due to its attractive dividend yield of approximately 6.9% [1][7] Dividend and Financial Performance - Pfizer's current payout ratio stands at 51% of earnings, reflecting a commitment to returning profits to shareholders while also reinvesting in growth [2][3] - The company has increased its dividend five times over the past five years, with an annualized dividend growth of 2.56% [3][2] - In the first half of the year, Pfizer reported cash inflows of $571 million against dividend payments of $4.9 billion, but the CFO has assured improvements in cash flows for the second half [3][4] Revenue and Growth Prospects - Pfizer's Q2 revenues reached $14.7 billion, marking a 10% year-over-year increase, with EPS rising 30% to $0.78 [7][9] - The company is launching new drugs, such as Elrexfio and Sigvotatug vedotin, to offset revenue losses from the loss of exclusivity of some best-selling drugs [4][5] - The acquisition of Seagen is expected to enhance cash flow, providing financial flexibility for sustaining and increasing dividends [5][8] Market Position and Competitive Landscape - Pfizer's sales for its COVID-19 products, Paxlovid and Comirnaty, have shown year-over-year growth, alongside strong performance from cancer drugs like Xtandi and Padcev [9] - Despite positive indicators, challenges remain, including competition in the immuno-oncology space and patent expirations for key products like Eliquis and Xtandi [12] Technical Indicators - A golden cross pattern has emerged, indicating a potential uptrend in Pfizer's share price, as the 50-day moving average has crossed above the 200-day moving average [10]

Core Viewpoint - Pfizer is highlighted as a top dividend-paying stock with strong value, offering a forward dividend yield of 6.86% and a low forward P/E ratio of 8.3, making it an attractive investment option in the current market [4][6]. Dividend Performance - Pfizer has a robust dividend history, having paid 347 consecutive quarterly dividends and increased its dividend for 16 consecutive years [4]. - The company's management prioritizes maintaining and growing the dividend, despite a high payout ratio of around 90% [5]. Financial Metrics - The forward P/E ratio of Pfizer is significantly lower than the S&P 500's average of 22.8 and the healthcare sector's average of 16.5, indicating strong value [6]. - Analysts project a consensus 12-month price target for Pfizer that reflects an upside potential of over 13%, with a low PEG ratio of 0.86 suggesting confidence in its growth prospects [9]. Patent Cliff and Growth Prospects - Pfizer faces a patent cliff with several top-selling products losing exclusivity, including Eliquis and Ibrance, which generated $7.6 billion and $4.4 billion in sales, respectively [7]. - The company has a promising pipeline with 108 candidates, including late-stage programs and new products like Nurtec ODT and Abrysvo, which are expected to drive future growth [8]. Market Sentiment - Wall Street appears optimistic about Pfizer's ability to navigate challenges, as indicated by the consensus price target and low PEG ratio, suggesting that analysts are not overly concerned about the impact of patent expirations on growth [9].